Sera Prognostics (NASDAQ:SERA) Releases Earnings Results, Misses Estimates By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) released its quarterly earnings data on Wednesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.03), FiscalAI reports. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 44.27% and a negative net margin of 47,475.72%.

Here are the key takeaways from Sera Prognostics’ conference call:

• Positive Sentiment: Illinois enacted Medicaid coverage legislation for prescribed proteomic tests and related care management for spontaneous preterm-birth risk, potentially providing access to approximately 50,000 eligible births annually. Sera has begun contracting, credentialing, provider education, and workflow integration, though meaningful utilization is expected to ramp gradually.
• Positive Sentiment: Payer engagement exceeded the company’s 2026 goal, reaching more than 20 opportunities across over 20 states, while Sera launched its fourth commercial partnership and remains on track for five to seven programs. Management expects the pipeline to contribute more meaningfully as opportunities move through implementation and contracting, typically a six- to nine-month process.
• Positive Sentiment: New PRIME data in first-time mothers showed a 22% reduction in NICU admissions and a 30% reduction in severe composite neonatal morbidity, with one NICU admission prevented for every 28 patients screened and treated. The findings and upcoming SMFM presentations are intended to support broader clinical adoption and future guideline inclusion.
• Negative Sentiment: Revenue remained very modest at $30,000, despite month-to-month increases in testing volume, while the net loss widened to $9.1 million from $8.0 million year over year. Sera ended the quarter with $80.3 million in cash and expects it to fund operations through 2029, but near-term commercial conversion remains limited.
• Negative Sentiment: Sera moved its expected European CE-marking submission to the fourth quarter after deciding to conduct additional ELISA assay performance testing to reduce execution risk. Management remains confident in the regulatory plan, but the timing shift delays a potential European commercialization milestone.

Sera Prognostics Price Performance

Shares of SERA stock opened at $2.01 on Friday. Sera Prognostics has a 1-year low of $1.56 and a 1-year high of $3.95. The firm has a market cap of $78.71 million, a PE ratio of -3.00 and a beta of 0.96. The company has a 50-day moving average of $1.99 and a two-hundred day moving average of $2.11.

Insider Activity

In other news, CEO Zhenya Lindgardt sold 20,755 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $43,170.40. Following the transaction, the chief executive officer directly owned 871,999 shares in the company, valued at approximately $1,813,757.92. This represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 27,755 shares of company stock valued at $57,840. 11.30% of the stock is currently owned by insiders.

Institutional Trading of Sera Prognostics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SERA. Qube Research & Technologies Ltd purchased a new position in shares of Sera Prognostics during the second quarter worth $92,000. Captrust Financial Advisors raised its holdings in shares of Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after buying an additional 100,366 shares during the period. Corient Private Wealth LLC lifted its stake in Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after acquiring an additional 42,500 shares in the last quarter. Vanguard Group Inc. lifted its stake in Sera Prognostics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after acquiring an additional 54,008 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after acquiring an additional 7,643 shares during the period. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Wall Street Analysts Forecast Growth

SERA has been the topic of a number of recent analyst reports. Craig Hallum started coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings downgraded shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sera Prognostics has a consensus rating of “Moderate Buy” and an average price target of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.